Bioinvent International Ab Stock Net Income
| BOVNF Stock | USD 3.29 0.00 0.00% |
Fundamental analysis of BioInvent International allows traders to better anticipate movements in BioInvent International's stock price by examining its financial health and performance throughout various phases of its business cycle.
BioInvent |
BioInvent International AB Company Net Income Analysis
BioInvent International's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current BioInvent International Net Income | (278.44 M) |
Most of BioInvent International's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioInvent International AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, BioInvent International AB reported net income of (278.44 Million). This is 181.59% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is 148.77% higher than that of the company.
BioInvent Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioInvent International's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioInvent International could also be used in its relative valuation, which is a method of valuing BioInvent International by comparing valuation metrics of similar companies.BioInvent International is currently under evaluation in net income category among its peers.
BioInvent Fundamentals
| Return On Equity | -0.0274 | |||
| Return On Asset | -0.0192 | |||
| Profit Margin | (0.14) % | |||
| Current Valuation | 183.41 M | |||
| Shares Outstanding | 65.8 M | |||
| Shares Owned By Insiders | 11.10 % | |||
| Shares Owned By Institutions | 57.02 % | |||
| Price To Earning | (8.68) X | |||
| Price To Book | 2.32 X | |||
| Price To Sales | 11.53 X | |||
| Revenue | 19.38 M | |||
| Gross Profit | 19.38 M | |||
| EBITDA | (263.32 M) | |||
| Net Income | (278.44 M) | |||
| Cash And Equivalents | 12.18 M | |||
| Cash Per Share | 0.04 X | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 23.60 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (245.84 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 93 | |||
| Beta | 0.3 | |||
| Market Capitalization | 309.28 M | |||
| Total Asset | 1.45 B | |||
| Net Asset | 1.45 B |
About BioInvent International Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioInvent International AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioInvent International using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioInvent International AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in BioInvent Pink Sheet
BioInvent International financial ratios help investors to determine whether BioInvent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioInvent with respect to the benefits of owning BioInvent International security.